NCT07089719View on ClinicalTrials.gov

Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

May 1, 2028

Conditions
Dyspnea Caused by 2019-nCoV
Interventions
DRUG

Bevacizumab Injection

Participants will receive Bevacizumab at a dose of 10mg/kg via intravenous infusion. They will receive a total of 5 injections, administered every two weeks.

Trial Locations (2)

75015

HEGP, clinical investigation center, Paris

HEGP, department of Physiology, Paris

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER